Compare SKWD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | MESO |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2022 | 2005 |
| Metric | SKWD | MESO |
|---|---|---|
| Price | $58.76 | $14.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $70.45 | $37.00 |
| AVG Volume (30 Days) | ★ 310.2K | 192.9K |
| Earning Date | 11-05-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,416,541,000.00 | N/A |
| Revenue This Year | $39.34 | $59.17 |
| Revenue Next Year | $6.68 | $59.00 |
| P/E Ratio | $27.33 | ★ N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $40.60 | $13.05 |
| 52 Week High | $65.69 | $21.50 |
| Indicator | SKWD | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 43.02 |
| Support Level | $55.18 | $14.18 |
| Resistance Level | $58.81 | $15.97 |
| Average True Range (ATR) | 1.47 | 0.37 |
| MACD | 0.59 | -0.06 |
| Stochastic Oscillator | 83.12 | 31.30 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.